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Abstract
Mitogen activated protein kinases (MAPKs) are highly conserved protein kinase
modules and they control fundamental cellular processes. While the activation
of MAPKs has been well studied, little is known on the mechanisms driving their
inactivation. Here we uncover a role for ubiquitination in the inactivation of a
MAPK module.  Extracellular-signal-Regulated  Kinase  5  (ERK5) is  a  unique,
conserved member of the MAPK family and is activated in response to various
stimuli  through  a  three-tier  cascade  constituting  MEK5  and  MEKK2/3.  We
reveal  an  unexpected  role  for  Inhibitors  of  Apoptosis  Proteins  (IAPs)  in  the
inactivation of ERK5 pathway in a bimodal manner involving direct interaction
and ubiquitination.  XIAP directly  interacts  with  MEKK2/3  and competes with
PB1  domain-mediated  binding  to  MEK5.  XIAP  and  cIAP1  conjugate
predominantly K63-linked ubiquitin chains to MEKK2 and MEKK3 which directly
impedes  MEK5-ERK5  interaction  in  a  trimeric  complex  leading  to  ERK5
inactivation. Consistently, loss of XIAP or cIAP1 by various strategies leads to
hyperactivation  of  ERK5  in  normal  and  tumorigenic  cells.  Loss  of  XIAP
promotes differentiation of human primary skeletal myoblasts to myocytes in a
MEKK2/3-ERK5 dependent manner. Our results reveal a novel, obligatory role
for  IAPs  and  ubiquitination  in  the  functional  disassembly  of  ERK5-MAPK
module and human muscle cell differentiation.
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Introduction 
Mitogen Activated Protein Kinases (MAPKs) are highly conserved, ubiquitously
expressed enzymes that are activated in response to a plethora of extracellular
stimuli  to  regulate  a  variety  of  cellular  processes  .  Typically,  MAPKs  are
activated by dual phosphorylation in the Thr-X-Tyr motif in their activation loop
by a MAPKK. MAPKKs on the other hand, are activated by phosphorylation of
Ser-Thr residues by upstream MAPKKKs thus constituting a three tier kinase
cascade .  RAF-MEK1/2-ERK1/2 is the first  discovered, well-studied classical
MAPK cascade. In mammalian cells, four distinct classical MAPK cascades are
recognized: ERK1/2, JNK1/2/3, p38 MAPK α/β/γ/δ and the ERK5 pathways .
ERK5, also called the Big MAPK 1 (BMK1) was cloned by two groups in 1995. It
is a unique member of this family as it  is double the size of ERK1/2 with a
kinase domain in the N-terminus and a long C-terminus . The N-terminal kinase
domain is  66% identical  to  the kinase domain of  ERK2 and the C-terminus
encompasses a nuclear localisation signal (NLS), two proline rich domains, a
myocyte  enhancer  factor  2  (MEF2)-interacting  region  and  a  transcriptional
activation domain . MEK5 was identified as an upstream MAPKK through yeast
two-hybrid analysis, phosphorylating the activation loop of ERK5 at Thr218 and
Tyr220  leading  to  its  activation  .  Activated  ERK5  undergoes
autophosphorylation  at  numerous  residues  in  its  C-terminus,  which  causes
conformational  change  so  that  the  NLS  is  exposed,  facilitating  its  nuclear
translocation . MEKK2 and MEKK3 kinase domains are 90% identical and they
form heteromers with  MEK5 through their  PB1 (Phox,  Bemp1)  domains,  an
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evolutionarily conserved protein-protein interaction motif . MEKK2/3 and MEK5
interact through their PB1 domains in a front-to-back orientation where the basic
residues  in  the  front  end  of  MEKK2/3  PB1  domain  mediate  electrostatic
interactions with the acidic residues in the back end of MEK5 PB1 domain .
ERK5, though lacks the PB1 domain, interacts through its N-terminus (a.a. 78-
139) with the PB1 domain and the following C-terminal stretch (a.a. 98-131) of
MEK5 . Like many MAPKs, ERK5 possesses a common docking domain (a.a.
350-358) with negatively charged amino acids, with which it interacts with its
substrates  and  MEK5  consequently  maintaining  the  signaling  fidelity  and
efficiency  .  The  ERK5  cascade  is  activated  in  response  to  various  growth
factors (EGF, PDGF, VEGF, FGF-2, NGF and BDNF), cytokines (like IL-6) and
other stimuli like oxidative stress and ischemia. Gene knock out studies have
revealed a crucial role of this cascade in the development of cardio vascular
system . There is mounting evidence for the role of ERK5/MAPK pathway in
regulating cancer as ERK5 amplifications (17p11) are detected in hepatocellular
carcinoma and  high  MEK5 and  ERK5 levels  are  associated  with  bone  and
lymph node metastases in prostate cancer and oral squamous cell carcinoma,
respectively . Despite the physiological and patho-physiological importance of
the ERK5 signaling cascade, relatively less is known on the upstream signaling
machinery as well as the factors contributing to the activation/inactivation of this
pathway. Here we identify Inhibitors of Apoptosis Proteins (IAPs) as negative
regulators of ERK5 activation.
Inhibitors  of  apoptosis  proteins  are  a  class  of  evolutionarily  conserved,
multifunctional  proteins  .  In  mammals,  eight  IAPs exist  distinguished by  the
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presence of their signature BIR (Baculo viral IAP Repeat) domain, a conserved
protein-protein interaction motif. Many of them possess a RING domain with E3
ubiquitin ligase activity . X-linked inhibitor of apoptosis protein (XIAP, also called
BIRC4) is considered as a legitimate inhibitor  of caspases and cellular IAPs
(cIAPs) were shown to control both canonical and non-canonical pathways of
NFκB  activation  .  Apart  from  their  well-established  role  in  apoptosis,
inflammation and innate immunity, emerging evidence revealed a role for IAPs
in the regulation of cell shape, cell migration and tumor metastases . XIAP and
cIAPs regulate classical MAPK activation as they can promote the proteasomal
degradation of C-RAF through the Hsp90 protein quality control  machinery .
Further  XIAP  and  cIAP1  can  function  as  the  direct  E3  ubiquitin  ligase  of
RhoGTPase Rac1, thus controlling cell shape and migration . Here we uncover
that XIAP and cIAP1 function as negative regulators of ERK5 signaling cascade
by  physically  interacting  with  and  ubiquitinating  MEKK2  and  MEKK3.  As  a
consequence, loss of XIAP enhances ERK5 activation and MEF2C activity. This
in  turn  promotes  human  myoblast  differentiation  in  a  MEKK2/3-ERK5
dependent  manner.  Our  results  reveal  a thus far  unknown role of  IAPs and
ubiquitination in the functional disassembly of a classical MAPK module and
human myocyte generation. 
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Results
Loss of IAPs leads to hyperactivation of ERK5 in normal and tumor cells
We have recently shown that XIAP and cIAPs can modulate ERK1/2 activation
by directly regulating the stability of C-RAF kinase . To test if XIAP can influence
other related classical MAPKs, we checked for the activation of ERK5 (pERK5)
in IAP depleted cells. Interestingly, depletion of XIAP with different siRNAs led
to a striking increase in the phosphorylation of ERK5 at steady state in HeLa
cells (Figure 1A, B). Loss of XIAP did not lead to any significant alterations in
the protein levels of ERK5 (Figure 1A, B). Similarly, depletion of cIAP1 but not
cIAP2 led to an increase in ERK5 phosphorylation in these cells (Figure S1A,
1B). These effects were evident in other tumor cell lines as well as in human
primary  tracheal  epithelial  cells  (Figure  S1C,  S1D and data  not  shown).  To
exclude  any  potential  off  target  effects,  we  performed  complementation
experiments. Expression of XIAP in trans reduced pERK5 levels in HeLa cells
transfected with 3’UTR-XIAP siRNA (Figure S1E) thus confirming the specificity
of the observed phenotype. To corroborate these observations, we checked for
MEF2 transcriptional activity in HeLa cells stably expressing MEF2 luciferase
reporter  constructs.  Consistent  with  the  previous  observations,  depletion  of
XIAP led  to  a  significant  increase  in  MEF2  activity  in  an  ERK5 dependent
manner (Figure 1C). Further, we checked for the kinetics of ERK5 activation in
HeLa cells and MEFs. Loss of XIAP increased ERK5 activation in HeLa cells
and MEFs in response to FCS and FGF-2 stimulation, respectively (Figure 1B
and  1D).  This  suggests  that  loss  of  XIAP influences  the  intensity  of  ERK5
activation. As XIAP loss can lead to stabilization of C-RAF and Rac1 protein
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levels, we checked for their possible role in the activation of ERK5. Co-knock
down experiments  in  HeLa  cells  revealed  that  depletion  of  XIAP led  to  an
increase in pERK5 levels despite the absence of C-RAF and Rac1 (Figure S1F-
S1H). As MEKK2/3 and MEK5 are the cognate upstream MAPK members, we
checked for their role in activating ERK5 in XIAP depleted cells. As expected,
co-knock down of MEKK2, MEKK3 or MEK5 prevented activation of ERK5 in
XIAP depleted cells  (Figure 1E-1G).  These results  confirmed that  XIAP and
cIAP1 negatively regulate ERK5 activation. Further, depletion of both MEKK2
and  MEKK3  led  to  reduced  ERK5  activation  unveiling  functional  non-
redundancy between these two MAP3Ks in  activating  MEK5-ERK5 pathway
(Figure 1E, 1F). 
XIAP  directly  binds  to  MEKK2/3  and  competes  with  MEK5  for  PB1-
mediated interaction 
As XIAP has been shown to interact with MEKK2 , we checked if this is a direct
interaction. In vitro interaction experiments with purified recombinant proteins
revealed a direct interaction between XIAP and MEKK2 or MEKK3 (Figure 2A).
Consistently, we could detect XIAP-MEKK2 interaction at endogenous levels in
HeLa  cells.  However,  we  failed  to  detect  MEKK2  or  MEKK3  in  XIAP
immunoprecipitates (Figure 2B and data not shown). We then checked for the
role of various domains of XIAP in mediating the interaction with MEKK2. In
vitro  interaction  experiments  with  purified  proteins  encompassing  various
domains  of  XIAP (Figure  S2A)  revealed  that  the  RING  domain  of  XIAP is
dispensable  for  binding  to  MEKK2 and that  this  interaction  can possibly  be
mediated through BIR1 and BIR2 domains (Figure S2B). Next, we investigated
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the  role  of  PB1  domain  of  MEKK2  in  mediating  the  interaction  with  XIAP,
although XIAP did  not  possess any PB1 domain.  Interestingly,  mutating the
conserved basic lysine residue in the PB1 domain (K47A) severely impaired the
direct interaction between XIAP and MEKK2 (Figure 2C). As XIAP binds to the
PB1 domain of MEKK2, we expected a potential competition between XIAP and
MEK5 in binding to MEKK2. XIAP fails to bind directly to MEK5 (Figure 2D). In
vitro competition experiments with recombinant full-length proteins revealed that
XIAP could  directly  compete  with  MEK5  in  binding  to  MEKK2  (Figure  2E).
Consistent with these observations, we could detect increasing amounts (~1.5
fold)  of  MEK5  co-precipitating  with  MEKK2  at  endogenous  levels  in  XIAP
depleted cells (Figure 2F and S2C). These results revealed that XIAP could
directly bind to MEKK2/3 and compete with MEK5 interaction.
XIAP regulates ERK5 activation in a RING dependent manner
As XIAP possesses a RING domain with E3 ubiquitin ligase activity, we
tested for the role of RING domain in regulating ERK5 activation. To check for
potential ubiquitination of MEKK2, we immunoprecipitated endogenous MEKK2
from control  and  XIAP deficient  MEFs  stimulated  with  FGF-2.  Upon  FGF-2
stimulation, ERK5 phosphorylation increased and was inactivated at 15 minutes
post  induction  in  control  cells.  Interestingly,  XIAP  deficient  cells  exhibited
pronounced ERK5 phosphorylation at 15 minutes post induction (Figure 3A).
Intriguingly, the MEKK2 antibody detected a smear at 15 minutes post induction
in control cells, which was clearly absent in the XIAP deficient cells (Figure 3A).
Furthermore, the appearance of MEKK2 smear correlates with the inactivation
phase of ERK5. We then checked for direct ubiquitination of MEKK2/3 by XIAP
or cIAP1. Ubiquitination experiments revealed that XIAP and cIAP1 can directly
ubiquitinate MEKK2 and MEKK3 in vitro (Figure 3B, S3A and S3B). In addition,
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we  have  also  detected  autoubiquitination  of  the  respective  IAPs  in  these
reactions  (data  not  shown).   As  the  ubiquitin  smears  were  detected  in  the
absence of  any proteasomal  inhibitors (Figure 3A),  we suspected that  XIAP
might  conjugate  non-degradative  ubiquitin  chains  on  MEKK2  and  MEKK3.
Recent studies revealed that several kind of ubiquitin chains ( K-63, K-11, M0,
K27/29 and K6)  are involved in  signaling  and in  the assemblage of  protein
complexes . By employing linkage specific antibodies and ubiquitin mutants, we
detected  that  XIAP and  cIAP1 conjugate  predominantly  K63-linked  ubiquitin
chains to MEKK2 and MEKK3 both in vitro and in vivo (Figure 3C-3E and S3C-
S3E). To confirm these observations, we employed K-63 ubiquitin-specific DUB
AMSH  ([associated  molecule  with  the  Src  homology  3  domain  of  signal
transducing adaptor molecule (STAM)].  As expected, AMSH treatment led to
deubiquitination  of  MEKK2  similar  to  Usp2  suggesting  that  the  chains
synthesized on MEKK2 by XIAP are predominantly K-63 linked chains (Figure
S3F). Consistently, MEF2 luciferase activity induced by MEKK2 is impaired by
co-expression of XIAP (Figure S3G). Subsequently, we examined the role of
ubiquitination in regulating the activation dynamics of ERK5. To pursue these
experiments, we employed MEFs derived from XIAP ΔRING knock-in mice or
MEFs derived from XIAP knockout mice complemented with either wild type or
XIAP-H467A, a RING mutant of XIAP. Interestingly, the activation of ERK5 is
sustained in XIAP ΔRING MEFs as loss of the RING domain of XIAP enhanced
the basal as well as FGF-2-mediated activation of ERK5 (Figure 3F). Similarly,
stable expression of wild type XIAP, but not XIAP-H467A, rescued FGF-induced
ERK5  overactivation  in  the  XIAP  deficient  MEFs (Figure  3G).  Finally,  we
attempted mass spectrometry based approach to identify the ubiquitination sites
on MEKK2 and MEKK3 (Figure S4).  Interestingly,  most  of  the ubiquitination
sites identified in this screen were primarily localized in the kinase domains of
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MEKK2 or MEKK3. Mutation of these individual lysine residues failed to prevent
direct ubiquitination of MEKK2 or MEKK3 by XIAP suggesting that these sites
are  probably redundant  (data  not  shown).  However,  transfection  of  MEKK2-
K450R  mutant  increased  pERK5  levels  at  steady  state  suggesting  that
ubiquitination at this site is possibly involved in the activation dynamics of ERK5
(Figure S4C). 
Ubiquitination of MEKK2 and MEKK3 does not impair their kinase activity
but impedes ERK5 activation
As IAPs directly ubiquitinate the kinase domain of MEKK2 and MEKK3, we then
tested if ubiquitination of MEKK2 or MEKK3 directly alters its kinase activity or
its  interaction  with  the  downstream  MAP2K,  MEK5.  We  conducted  in  vitro
ubiquitination-coupled  phosphorylation  assays  to  measure  the  activity  of
ubiquitin-conjugated or non-ubiquitinated MEKK2. Ubiquitination of MEKK2 or
MEKK3 did not impair the direct phosphorylation of MEK5 (Figure 4A and data
not shown). Similar results were obtained in  in vitro kinase assays employing
P32 with  MEKK3  using  myeline  basic  protein  (MyBP),  a  common  kinase
substrate (Figure 4B). As XIAP-mediated ubiquitination fails to impair the kinase
activity of MEKK2/3 directly, we performed in vitro reconstituted kinase assays
with the entire MEKK2/3-MEK5-ERK5 kinase module components. Mutationally
inactivated  ERK5,  ERK5_KI  D182A  was  used  in  all  kinase  experiments.
Consistent  with  the  previous  observations,  we  detected  efficient  ERK5
phosphorylation  with  non-ubiquitinated  MEKK2  or  MEKK3  but  not  with
ubiquitinated kinases suggesting that  ubiquitination of MEKK2 or MEKK3 by
IAPs has a direct influence on the activation of ERK5 in a trimeric complex
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(Figure 4C). We employed concentrations of XIAP that will not compete with the
interaction between MEKK2/3 and MEK5 in these experiments. Further, in the
absence of E1 and E2 (or ubiquitination), ERK5 phosphorylation is not inhibited
under  these  conditions  (Figure  S5A).  In  addition,  we  detected  that
phosphorylation of ERK5 but not MEK5 is impaired in these coupled assays
suggesting that ubiquitination of MEKK2/3 has a direct effect on the activation of
ERK5  (Figure  4D).  Further,  XIAP  auto-ubiquitination  fails  to  prevent  ERK5
phosphorylation in the presence of constitutively active MEK5 (MEK5DD) and
thus,  XIAP  requires  ubiquitination  of  MEKK2/3  for  impairing  ERK5
phosphorylation (Figure 4E). MEKK2/3 kinases also activate the JNK pathway
by directly phosphorylating and activating MKK7. To confirm if  the observed
effect of ubiquitination is specific for the ERK5 kinase module we conducted
similar  experiments  with  purified  MEKK2/3,  MKK7  and  JNK1.  Interestingly,
ubiquitination of MEKK2/3 by XIAP failed to prevent JNK1 phosphorylation in
these coupled assays (Figure S5B). These results revealed a direct, specific
role for ubiquitinated MEKK2 and MEKK3 in negatively regulating the activation
of ERK5 but not JNK1.
Ubiquitination promotes MEKK2/3 dimerization but directly impairs MEK5-
ERK5 interaction 
As ubiquitination is not influencing the kinase activity of MEKK2 and MEKK3 we
checked for the complex formation. MEKK2 and MEKK3, like many kinases, are
activated  by  dimerization  via their  catalytic  domain  and  they  form  weak
homodimers. Consistent with the kinase activity of ubiquitin conjugated MEKK2,
ubiquitination directly promoted homo- as well as heterodimerization of MEKK2
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with MEKK3 (Figure 5A and 5B). We then checked if ubiquitination impairs the
interaction between MEK5 and MEKK2/3. Ubiquitination of MEKK2 or MEKK3
by XIAP did not impair the interaction with MEK5 (Figures 5C and 5D). The PB1
domain  of  MEK5  co-ordinates  the  interaction  between  the  PB1  domain  of
MEKK2/3 and the N-terminus of ERK5 to form a kinase competent complex
(Figure 5E) . While the PB1-mediated interaction between MEKK2/3 and MEK5
is mediated  via electrostatic interactions, ERK5 interaction with MEK5 is non-
canonical as ERK5 lacks a PB1 domain . We envisaged that ubiquitination of
MEKK2/3  might  compete  with  MEK5-ERK5 interaction  as  PB1 domain  also
presents an ubiquitin-like β-grasp fold . We then repeated the assays with all
three kinases and checked for the formation of the entire kinase module. As
expected,  ubiquitinated  MEKK2/3  prevented  the  direct  interaction  between
MEK5 and ERK5 in a trimeric complex (Figure 5F, 5G and S6A). To confirm
these observations in cells, we have attempted to immunoprecipitated the entire
kinase  module  from cells  stably  expressing  ERK5  and  MEK5.  Interestingly,
increasing amounts of MEK5 was co-precipitating with ERK5 in the absence of
XIAP (Figure S6B).  Taken together, these data suggest that ubiquitin chains
conjugated  to  MEKK2/3  directly  prevented  the  non-canonical  interaction
between MEK5 and ERK5 thus inactivating ERK5-MAPK module (Figure 5G).
This effect is specific for ERK5 module as ubiquitination of MEKK2/3 kinases
failed to prevent MKK7 or JNK1 activation under identical settings (Figure S5B).
Loss of XIAP promotes MEF2 activity and human myoblast differentiation 
As  XIAP  negatively  regulates  ERK5  activation  by  direct  interaction  and
ubiquitination,  we  investigated  the  physiological  significance  of  these
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observations. ERK5 regulates neuronal and muscle differentiation through the
activation  of  MEF2  transcription  factors  .  Consequently,  we  explored  the
possible role of  XIAP in the regulation of human primary skeletal  myoblasts
(HSM)  differentiation.  Human  primary  skeletal  myoblasts  differentiate  to
myocytes in a span of 6-7 days as evidenced by the formation of polynucleated
myotubes and expression of differentiation markers like Myosin Heavy Chain
(MHC),  MEF2C,  MyoD  and  p21.  We  initially  checked  if  depletion  of  XIAP
modulates ERK5 activation in HSM cells. As expected, depletion of XIAP led to
an increase in pERK5 signals in the immunoblots and MEF2 activity in HSM
cells (Figure 6A and 6B). Consistently, loss of XIAP strongly promoted (~10-12
fold increase) the differentiation of myoblasts as evidenced by the presence of
polynucleated  muscle  fibers  with  a  strong  staining  of  Myosin  heavy  chain
(Figure 6C and 6D). Immunoblot analysis revealed that loss of XIAP led to a
consistent  increase  in  pERK5  levels  with  a  concomitant  increase  in  the
appearance of various differentiation markers including MHC, p21, Myogenin
and MEF2C (Figure 6E and 6F). As cIAP1 loss also leads to ERK5 activation in
tumor cells, we initially tested for the role of cIAP1 in regulating human myoblast
differentiation. However, single depletion of cIAP1 failed to enhance myocyte
formation possibly due to cross stabilization of XIAP in these cells (ANT, KR
unpublished observations). These results confirmed that loss of XIAP promotes
ERK5 activation and myogenesis in human cells. 
XIAP  regulates  human  myogenic  differentiation  in  MEKK2/3-ERK5
dependent manner
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We then investigated if the enhanced differentiation observed in XIAP depleted
HSM  cells  were  indeed  due  to  the  hyperactivation  of  ERK5  signaling.  To
address  this  issue,  we  performed  several  co-knock  down  experiments.
Interestingly, knock down of ERK5, MEKK2 and MEKK3 completely prevented
both basal as well as siXIAP-mediated differentiation of myoblasts (Figure 7A-
7G and S8A, S8B).  To corroborate these observations,  we employed ERK5
specific kinase inhibitor XMD 8-92. Consistent with the observations made with
ERK5 siRNAs, treatment of HSM cells with XMD 8-92 prevented both normal
and  XIAP-depletion  induced  differentiation  as  evidenced  by  the  lack  of
polynucleation  or  expression  of  differentiation  markers  (Figure  7C,  7D  and
S7C). These results confirmed the physiological role of XIAP-ERK5 interface in
human myogenic differentiation. 
Discussion
MAPKs are  activated in  response to  various stimuli  to  perform fundamental
cellular processes . The signaling fidelity and efficiency of MAPK modules are
controlled by scaffolding proteins and docking interactions occurring in a spatio-
temporal  manner  .  Dephosphorylation  by  phosphatases is  one of  the  major
means of inactivating MAPKs .  The cross talk between phosphorylation and
ubiquitination  is  multilayered  and  there  is  a  lot  of  evidence  for  the  role  of
ubiquitination in the regulation of kinase activity . To the best of our knowledge,
this the first evidence where non-degradative ubiquitination (predominantly K63-
linked  ubiquitin)  is  involved  in  the  physical  and functional  disassembly  of  a
“classical”  MAPK  module,  thus  adding  another  layer  in  the  inactivation  of
MAPKs.  ERK5  is  a  relatively  less  studied  MAPK  despite  its  importance  in
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vertebrate development and in pathogenic conditions like cardiac hypertrophy
and cancer  .  The MEKK2/3-MEK5-ERK5 cascade is  activated by  numerous
stimuli  and  assembled  by  distinct  PB1  domain-mediated  protein-protein
interactions, though a role for scaffold proteins like Lad has been suggested .
This study reveals a novel role for IAP-mediated ubiquitination events in directly
uncoupling a MAPK from its cognate MAPKK. 
XIAP and cIAP1 are highly  conserved RING domain-containing  E3 ubiquitin
ligases and they can catalyse the conjugation of  ubiquitin  chains of  various
kinds to their growing list of substrates. We have previously shown that XIAP
can regulate Rac1 protein stability . While we fail to detect a significant role for
Rac1 in ERK5 activation ( Figure S1F,G) an upstream, cell type specific role in
activating MEKK2/3 cannot  be ruled out  as chemical  inhibition of  Rac1 has
been shown to reduce MEKK3 activation in T cells . XIAP and cIAP1 negatively
regulate ERK5 activation and as both IAPs are required, XIAP-cIAP1 complex is
possibly functional in vivo in regulating the ubiquitination of MEKK2/3.
In the same lines, both MAP3Ks are functionally non-redundant as depletion of
either  MEKK2 or  MEKK3 led to  an identical  reduction in  pERK5 levels  and
inhibition of myocyte formation. These data suggest that MEKK2 and MEKK3
might function as heterodimers (like B-RAF and C-RAF kinases) and that this
interaction could be stabilized by ubiquitination. In fact, ubiquitination of MEKK2
by XIAP promotes homodimerization and heteromerization with MEKK3 (Figure
5A and  5B).  IAPs  directly  conjugate  ubiquitin  predominantly  to  the  kinase
domains  of  MEKK2  and  MEKK3  and  ubiquitination  at  Lys450  in  MEKK2
contributes to the dynamics of ERK5 activation (Figure S4). Mutation of two or
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more lysine sites severely compromises the stability and expression of MEKK2
thus  limiting  further  studies.  We  have  however  characterized  the  kind  of
ubiquitin chains and their functional significance. Our mass spectrometry based
screen detects traces of K-11, K27/29 and K-48 chains apart from K-63 linked
chains. However,  by employing ubiquitin mutants,  linkage specific antibodies
and DUBs, we confirm that they are predominantly K-63 linked chains. Further
quantification  of  other  kind  of  chains  and  the  ubiquitination  sites  is  clearly
warranted. 
As expected, K63-linked ubiquitination of MEKK2/3 did not impair their kinase
activity as they still can directly phosphorylate MEK5 or MKK7. On the other
hand, in vitro reconstitution experiments revealed that ubiquitination of MEKK2
by  XIAP  decreases  the  MEK5-ERK5  interaction.  At  stoichiometric
concentrations  in  vitro,  ubiquitination  of  MEKK2/3  directly  and  completely
inhibits the activation of ERK5 but not JNK1 (Figure 5 and S5). Ubiquitination of
MEKK2 in vivo directly correlates to ERK5 dephosphorylation in cells in a XIAP
dependent manner (Figure 3A) and consistently, loss of RING activity or the
domain itself led to an increased ERK5 activation (Figure 3F,3G) confirming the
role  of  ubiquitination  in  this  process.  Ubiquitination  of  MEKK2  in  vivo “at
endogenous levels” seem to be partial (Figure 3A) but this could be either due
to a) the sensitivity of the antibody towards ubiquitinated MEKK2 in cells or b)
that  only  a  part  of  MEKK2  which  is  in  complex  with  MEK5-ERK5  gets
ubiquitinated. Further, interaction between the members of this kinase module
can also be regulated by compartmentalization within the cells. Thus  in vitro
reconstitution at stoichiometric concentrations is much needed to confirm the
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direct role of ubiquitin in the disassembly of this kinase module (Figure 5).  As
PB1 domain and ubiquitin are structurally similar ,  it  is quite likely that K63-
ubiquitin competes directly with the interaction between MEK5 and ERK5 but
not MKK7 and JNK1. In these lines, Seyfried  et al has previously shown that
MEKK2/3 and ERK5 can compete for binding to MEK5 PB1 domain . However,
recent structure based modelling studies confirmed that MEK5 PB1 domain can
indeed function as an adaptor as it involves two distinct surfaces for binding to
MEKK2/3  and  ERK5  .  Our  data  favor  an  ubiquitin-PB1  competition  model,
where K63-ubiquitin chains linked to MEKK2/3 prevent ERK5 from binding to
MEK5 thereby preventing ERK5 activation (Figure 5G and 7E).
Further, XIAP binds to the PB1 domain of MEKK2 as mutation of a conserved
lysine in this  domain prevents this interaction (Figure 2C) and loss of XIAP
enhances MEK5-MEKK2 interaction  in vivo (Figures 2F and S2D). We detect
XIAP-dependent ubiquitination of MEKK2 during the inactivation phase of ERK5
(Figure 3A) and thereof hypothesize that XIAP regulates ERK5 activation in a
two-step process. While XIAP limits MEKK2-MEK5 interaction at steady state
levels, stimulation of cells with FCS or growth factor triggers the ubiquitin ligase
activity  of  XIAP-cIAP1  complex  that  leads  to  the  conjugation  of  K63
polyubiquitin to MEKK2/3. This excludes ERK5 from interacting with MEK5, in
turn  leading  to  ERK5  inactivation  (Figure  7H).  Thus,  loss  of  XIAP  led  to
increased  ERK5  phosphorylation  both  at  steady  state  and  at  stimulated
conditions. It is currently unclear if the kinase activity of MEKK2 or MEKK3 is
required for interaction with XIAP. Currently, we lack sensitive tools to detect the
dynamics  of  interaction  between  MEKK2/3  and  XIAP  in  these  cells  at
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endogenous levels.  Further,  the upstream regulators of MEKK2/3 are largely
unknown  though  WNK1  has  been  suggested  to  function  as  an  upstream
kinase . 
Apart from the negatively regulatory role in ERK5 activation, what could be the
significance of  IAP-mediated MEKK2/3 ubiquitination? Previous studies have
shown that XIAP can also regulate the second wave of TNFα dependent NFκB
activation by binding to MEKK2 . Further, MEKK2 binds to MEK5 at steady state
levels  and  to  MKK7  upon  sorbitol  treatment  to  mediate  JNK  activation  .
Ubiquitination  of  MEKK2/3  by  IAPs  did  not  inactivate  these  kinases.  This
suggests that the ubiquitinated MEKK2/3 dimer might bind to other effectors like
MKK7.In  addition,  we  uncovered  that  MEKK2  is  a  ubiquitin  binding  protein
(KR,TKOK unpublished observations).`  Thus, XIAP-mediated ubiquitination of
MEKK2 might result in different outcomes depending on the external stimuli i.e.
TNFα triggering  late-phase  of  NFκB activation,  sorbitol  stimulating  JNK and
growth  factors  leading  to  ERK5  inactivation  and  regulation  of  cellular
differentiation (Figure 7H). In this context, it is interesting to point out that p62
can bind to MEKK3 to mediate NFκB activation . However, XIAP was reported
not to control the early phase of NFkB activation which is mediated by MEKK3 .
Further,  ubiquitination of  MEKK 2/3 failed to  prevent  the  activation  of  JNK1
directly unlike ERK5 (Figure S5). 
Consistent  with the negative regulatory role  of  XIAP in ERK5 activation,  we
uncover that depletion of XIAP augments activation of ERK5 and MEF2 thus
promoting the formation of human myotubes. Further, loss of MEKK2, MEKK3
and ERK5 led to a complete block in myogenic differentiation in control  and
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XIAP depleted cells. These data reveal the physiological significance of XIAP-
ERK5-cascade interactions in regulating human myogenic differentiation.
 While the role of IAPs in regulation of apoptosis, inflammation and immune
signaling  is  well  established,  their  role  in  regulation  of  cell  migration  and
differentiation is just emerging . cIAP1 has been previously shown to regulate
monocyte  to  macrophage  differentiation  and  NAIP,  to  regulate  neuronal
differentiation. TWEAK and cIAP1 have been shown to regulate myoblast fusion
through non-canonical pathway of NFκB . While cIAP1 functions as a direct E3
ligase  of  NIK,  loss  of  XIAP  does  not  lead  to  constitutive  NFκB  activation,
negating the possible  involvement of  this  pathway in XIAP-regulated human
myogenic differentiation. In this context, XIAP antagonists might be valuable in
treating  muscular  degenerative  diseases  and  for  promoting  muscle
regeneration. Taken together,  our data reveal  a novel role of IAPs and IAP-
mediated  non-degradative  ubiquitination  in  the  regulation  of  ERK5-MAPK
module and myogenic differentiation (Figure 7H). It would be indeed interesting
to investigate if  the assemblage and the activation dynamics of other MAPK
modules are also directly influenced by non–degradative ubiquitination. 
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Materials and methods
Cell culture
HeLa  and  A549  cells  were  cultured  in  RPMI-1640  medium  (Gibco  BRL)
supplemented  with  10%  FCS  (Gibco  BRL)  and  0.2%  penicillin  (100
U/ml)/Streptomycin (100 μg/ml)  (Gibco BRL) at  37°C in  5% CO2.  HEK293T,
A431 and BT474 were culture in DMEM medium supplemented with 10% FCS
(Gibco BRL) and 0.2% penicillin (100 U/ml)/Streptomycin (100 μg/ml) (Gibco
BRL) at 37°C in 5% CO2. HTEpC were cultured in Airway Epithelial Cell Growth
Medium from Promocell (C-21060). MEFs wt, MEFs XIAP -/- and MEFs XIAP-
ΔRING were obtained from John Silke and Hermann Steller and were cultured
in DMEM medium supplemented with 10% FCS (Gibco BRL), 0.2% penicillin
(100 U/ml)/Streptomycin (100 μg/ml) (Gibco BRL), 1 mM Non-Essential Amino
Acids, 1 mM Sodium Pyruvate and 1 mM β-Mercaptoethanol at 37°C in 5%
CO2. SKB are Human Skeletal Muscle Myoblast obtained from ZenBio (Cat #:
SKB-F (Lot 1 #: SK052009, Lot 2 #: SK051810)).  SKB were cultured in the
Skeletal  Muscle  Cell  Growth  Medium  (Cat  #:  SKM-M,  ZenBio)  and  were
differentiated with the Skeletal Muscle Cell Differentiation Medium (Cat #: SKM-
D, ZenBio) at 37°C in 5% CO2.
In order to obtain the HeLa MEKK2 wt, K450R and ERK5/MEK5 stable cell lines
we first transfected HEK293T with either pHAGE-CMV-N-Flag-HA-GAW-IRES-
Puro-MEKK2  wt  or  pHAGE-CMV-N-Flag-HA-GAW-IRES-Puro-MEKK2-K450R
or pHAGE-CMV-N-Flag-HA-GAW-IRES-PURO-ERK5 and pLenti4TO/V5-DEST-
MEK5 together with the pLenti package (HDM-VSV-G; HDM-tatlb; HDM-Hgprn2
(gag-pol); RC-CMV-Rev1b). The media containing the virus was sterile filtrated
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and then added to Hela cells in presence of  8 μg/μl  of  Polybrene.  After  24
hours, cells were selected with 2.5 μg/ml Puromycin or in the case of ERK5/
MEK5 overexpression with 2.5 μg/ml Puromycin and 100 μg/ml Zeocin. pHAGE
plasmid was a kind gift from Dr. Behrends. 
Wherever appropriate, cells were stimulated with FGF-2 (human FGFb147 from
eBioscience, Cat. No. 14-8986-80) in presence of serum for the indicated times
at  a final  concentration of  25 ng/ml.  In  case of  FCS stimulation,  cells  were
starved  for  15  hours  in  FCS-free  medium  and  then  stimulated  with  media
containing 10% FCS.
Transfection of siRNAs
In order to silence XIAP, cIAP1, cIAP2, MEKK2, MEKK3, MEK5, ERK5 and C-
RAF expression by siRNA interference approximately  75.000 cells/well  were
seeded in  12-wells  plate  at  least  20h  prior  to  transfection.  siRNAs directed
against various genes and scrambled control siRNA as negative control were
transfected at a final concentration of 60nM using Lipofectamine™ RNAiMAX
(Invitrogen,  Cat.  No.  13778)  transfection  reagent.  For  complementation
experiments, siRNA and plasmid were cotransfected using HiPerFect (QIAGEN,
Cat. No. 301705) transfection reagent. Unless otherwise mentioned, cells were
lysed  at  48h  post-transfection.  The  following  siRNAs  and  shRNAs  were
employed in this study (sense strand sequence):
siControl: 5’-UUCUCCGAACGUGUCACGU-3’ (QIAGEN, Cat. No. 1027310)
siXIAP #1 (3’utr): 5’-GACUGAUCUAAUUGUAUUATT-3’ (QIAGEN)
siXIAP #2:  5’-AAGTGCTTTCACTGTGGAGGA-3’ (QIAGEN, Hs_BIRC4_5_HP
Validated siRNA, Cat. No. SI00299446)
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siXIAP  #3:  5’-ACACUGGCACGAGCAGGGUUUCUUU-3’  (Invitrogen  Stealth,
XIAPHSS100564)
siXIAP  #4:  5’-GAAGGAGAUACCGUGCGGUGCUUUA-3’  (Invitrogen  Stealth,
XIAPHSS100565)
sicIAP1  #1:  5’-GAAUGAAAGGCCAAGAGUU-3’  (Thermo  Scientific,  ON-
TARGET plus siRNA human BIRC2 (329), Cat No. J-004390-13-0020)
sicIAP1  #2:  5’-CAGAAAGCUUUGAAUACUATT-3’  (QIAGEN,  Hs_BIRC2_12,
Cat No. SI05067258)
sicIAP1  #3:  5’-CAUAGUAGCUUGUUCAGUGTT-3’  (QIAGEN,  Hs_BIRC2_7,
Cat No. SI02654435)
sicIAP2 #1: 5’-UUGGGAACCGAAGGAUAAUTT-3’ (QIAGEN,
Hs_BIRC3_5_HP,  Cat No. SI00299439)
sicIAP2  #2: 5’-GCUGCAGAUUCGUUCAGAGUCUAAA-3’  (Invitrogen  Stealth,
BIRC3HSS100561)
siMEKK2:  5’-GCUACCCAGAUAAUCAUCAGGAAUU-3’  (Invitrogen  Stealth,
MAP3K2HSS116574)
siMEKK3:  5’-CUGACAACAGACAGGAAUA-3’  (SIGMA-ALDRICH,
SASI_Hs01_00047591)
siMEK5: 5’-AGGCCAGCACCUGAAGAAUTT-3’ (QIAGEN, Hs_MAP2K5_10_HP
validated siRNA, Cat. No. SI00300713)
siERK5:  5’-GACCCACCUUUCAGCCUUATT-3’  (QIAGEN,  Hs_MAPK7_9
validated siRNA, Cat. No. SI00606039)
siC-RAF (3’utr): GTGGATGTTGATGGTAGTACA (QIAGEN, target sequence)
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siRac1:  5’-AUGAAAGUGUCACGGGUAA-3’  (Thermo  Scientific,  siGENOME
siRNA human Rac1 (5879), D-003560-30-0020)
shC-RAF:  5’-CCGGCAAGCAAAGAACAGTGGTCAACTCGAGTTGACCACTG
TTCTTTGCTTGTTTTT-3’ (TRCN0000001067, Sigma-Aldrich)
shRac1:  5’-CCGGCCCTACTGTCTTTGACAATTACTCGAGTAATTGTCAAAGA
CAGTAGGGTTTTT (TRCN0000004872, Sigma-Aldrich)
Plasmids and constructs 
The eukaryotic expression plasmids are listed here: 
pGEX6p1-GST-XIAP  wt,  pGEX6p1-GST-XIAP-BIR1,  pGEX6p1-GST-XIAP-
BIR2,  pGEX6p1-XIAP-BIR3,  pGEX6p1-GST-XIAP-BIR1+2,  pGEX6p1-GST-
XIAP-BIR1+2+3,  pGEX6p1-GST-XIAP-ΔRING,  pgex6p1-GST-AMSH,
pcDNA3.1B-myc/his-XIAPwt,  pcDNA3.1B-myc/his-MEKK2  wt,  pcDNA3-flag-
MEKK2  wt,  pLenti4TO/V5-DEST-MEKK2  wt,  pHAGE-CMV-N-Flag-HA-GAW-
IRES-Puro-MEKK2  wt,  pcDNA3.1B-myc/his-XIAP  wt,  pEGZ-flag-XIAP  wt,
pRK5-HA-Ubiquitin wt.
The various point mutations in MEKK2 (K47A, K384M, K360R, K450R), XIAP
(H467A) and cIAP1 (H588A) were generated with a Site-Directed Mutagenesis
Kit (Stratagene) following manufacturer’s instructions.
SDS-Page and Western Blot
For SDS-Page, cells were lysed in 5X Laemmli buffer and boiled at 100°C for 5
min before loading onto polyacrylamide gels. The proteins were then transferred
to  nitrocellulose  membranes  by  western  blotting.  After  transfer,  membranes
were stained with Ponceau (AppliChem). For immunoblot analysis, membranes
were blocked with 5% low fat milk in Phosphate-Buffered Saline for 1 hour at
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room temperature and then incubated with various primary antibodies overnight
at  4ºC.  For  K63 linkage specific  antibody,  the  nitrocellulose membrane was
incubated for 2 hours at room temperature in the primary antibody and then
proceeded  as  stated  above.  Antigen  antibody  complexes  were  detected  by
horseradish peroxidase coupled secondary  antibodies followed by enhanced
chemiluminescence  (Amersham  Biosciences,  Millipore,  Thermo  Scientific).
Quantification  of  Western  Blots  was  performed  by  densitometry  (ImageJ
software, NIH). The following antibodies have been employed in this study: 
Phospho-ERK5  (Thr218/Tyr220;  Cat.  No.  3371)  and  total-ERK1/2  (p44/42
MAPKinase; Cat. No. 9102) rabbit polyclonal from Cell  Signaling; total-ERK5
(C-term, Cat. No. 1719-1), MEKK2 (Cat. No. 1662-1), MEKK3 (N-term, Cat. No.
1672-1) rabbit monoclonal and MEF2c (T300, Cat. No. T1324), MyoD (Cat. No.
S0549) rabbit polyclonal antibodies from Epitomics; XIAP (Cat.  No. 610763),
total-MEK5 (Cat. No. 610956) and Rac1 (Cat. No. 610650) mouse monoclonal
antibodies from BD Biosciences; Actin rabbit polyclonal (Cat. No. A2066) and
Tubulin (Cat. No. T9026), Flag (M2, Cat. No. F3165), GAPDH (clone GAPDH-
71.1, Cat. No. G8795) mouse monoclonal antibodies from Sigma-Aldrich; cIAP1
(1E1-1-10, Cat. No. ALX-803-335) and cIAP2 (16E-6-3, Cat. No. ALX-803-341)
rat antibody from ENZO; normal mouse IgG (Cat. No. sc-3877), normal rabbit
IgG (Cat. No. sc-3888), phospho-MEK5 (Ser311/Thr315; Cat. No. sc-135702),
C-RAF  (Raf-1,  C-12,  Cat.  No.  sc-133),  p21  (C-19,  Cat.  No.  sc-397)  rabbit
polyclonal, GST (B-14, Cat. No. sc-138) and HA (12CA5; Cat. No. sc-57592)
mouse monoclonal antibodies from Santa Cruz Biotechnology; Ubiquitin mouse
monoclonal antibody from Invitrogen (Cat. No. 13-1600); Goat anti-human IgG-
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HRP from  Invitrogen  (Cat.  No.  AHI0704);  MHC  (MF20)  mouse  monoclonal
antibody  from  DSHB;  Myogenin  mouse  monoclonal  antibody  from  Millipore
(Cat.  No.  MAB3876); Cy™3-conjugated  AffiniPure  Goat  Anti-Mouse  IgG
(Jackson  ImmunoResearch,  Code  No.  115-165-146).  The  antibody  against
K63-linked polyubiquitin was a kind gift from Genentech (San Fransisco, CA,
USA).
Luciferase Assay
HeLa cells were transduced with the Cignal Lenti Pathway Reporter lentiviral
particles using Cignal Lenti  MEF2 Reporter (luc) Kit (Qiagen, Cat.  No. CLS-
4024L).  Following  transduction,  the  cells  were  cultured  under  puromycin
selection  to  generate  a  homogenous  population  of  transduced  cells.  Briefly,
transduced  and  selected  HeLa  cells  were  seeded  on  a  12-well  plate  and
transfected  with  XIAP,  ERK5  and/or  MEKK2  siRNAs  using  Lipofectamine
RNAimax. 
HEK293T cells were transiently transfected with the Cignal MEF2 Reporter (luc)
Kit (QIAGEN, Cat. No. CCS-7024L). Cells were transfected using GeneJuice
(MERCK  Millipore,  Cat.  No.  70967)  with  500  ng  of  each  of  the  following
plasmids:  the  luciferase  reporter  gene,  MEKK2-myc/his  and  XIAP-flag.  As
negative and positive controls, we used the control plasmids provided by the
Kit.
In  both  case,  the  cells  were  harvested  in  Passive  Lysis  Buffer  48  h  after
transfection. The MEF2 Luciferase assay was performed using the Luciferase®
Reporter Assay System (Promega, Mannheim, Germany)  in accordance with
manufacturer’s protocol.
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Ubiquitination experiments
For  detecting  the  ubiquitination  of  MEKK2  in  vivo,  293T  cells  were
transfected with  flag-MEKK2 in  combination  with  HA-Ubiquitin  wt,  with  or
without  myc/his-XIAP  and  XIAP-H467A,  using  GeneJuice®  transfection
reagent (Novagen®, Merck Millipore, Cat. No. 70967) at a final concentration
of 1 μg/ml for 48 hours. The cells were lysed and immunoprecipitated with
Flag  antibody  for  15  hours  as  described  in  the  supplementary  methods
section.  The  bound  proteins  were  analyzed  by  SDS-PAGE  and
immunoblotting.
In vitro ubiquitylation of MEKK2 or MEKK3 was performed in the presence of
Ubiquitylation buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2.5 mM MgCl2,
1mM DTT), 100 nM XIAP or 100 nM c-IAP1 (R&D Systems), 100 nM E1
(Boston Biochem), 150 µM UbcH5a (Boston Biochem), 107 µM His-Ubiquitin
(Boston  Biochem),  50  mM  EDTA,  1X  Mg-ATP (Enzo  Life  Sciences),  1U
inorganic pyrophosphatase (Fluka) and 50 mM DTT. Wherever specified, in
vitro ubiquitination  was  performed using  K48-,  K63-  or  K29-only  ubiquitin
(Boston Biochem) . The reaction was incubated at 37C for 1h. For western
blot analyses, the reaction was stopped using Laemmli buffer and MEKK2
was visualized using MEKK2 rabbit monoclonal antibody (Epitomics).
For GST and His-Ubi Pull-down after  in vitro ubiquitination, 300 µl of GST
Pull-down buffer (GPB; constituents described in supplementary procedures)
was  added  to  the  in  vitro ubiquitination  reaction  mix  with  50  µl  of  either
equilibrated Glutathione sepharose or Ni-NTA beads. We then proceeded as
described  in  the  supporting  methods  for  GST-pull  down.  For
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immunoprecipitation  after  in  vitro ubiquitination,  300  µl  of  lysis  buffer
(constituents  described  above)  was  added  to  the  in  vitro ubiquitination
reaction  mix  with  2  µg  of  MEKK2  antibody  or  MEKK3  antibody  and
immunoprecipiated. For the deubiquitinase experiments, we treated  in vitro
ubiquitinated  MEKK2-GST  (SignalChem)  with  5  µM  Amsh  (K63  linkage
specific)  or  5  µM  Usp2  (linkage  unspecific)  for  60  min  at  30°C.  The
incubation was terminated by denaturation in Laemmli Buffer. 
Kinase Assay
For kinase assay, in vitro ubiquination of MEKK2 was performed as described
above,  with  or  without  the  addition  of  E3  ligase,  XIAP.  MEKK2  is
immunoprecipitated from these samples using MEKK2 antibody and sepharose
coupled protein  A/G beads according  to  procedure  described above.  Beads
were washed three times with lysis buffer and then the lysis buffer was removed
using insulin syringe. To the beads, added 4 µl of 10X kinase buffer (100 mM
MgCl2,  250  mM  β-Glycerophosphate,  250  mM  HEPES  pH  7.5,  50  mM
Bezamidine, 5 mM DTT, 10 mM Sodiumorthovanadate), 2 µl of 20X Mg-ATP
(Enzo Lifesciences), 400 ng of GST-MEK5 (Abcam) and distilled water up to 40
µl of reaction mix.  The reaction was incubated at 30°C for 30 min and then
stopped by adding 8 µl of 5X Laemmli. The entire reaction mix was loaded on
the SDS-PAGE gel for immunoblot analysis.
Proteins  for  the  MEKK2/3-MEK5-ERK5  and  MEKK2/3-MKK7-JNK1  MAPK
module reconstitution experiments were produced in  E.Coli or  in  SF9 insect
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cells  (with  the  baculoviral  expression  system)  as  N-terminal  GST  or  MBP
fusions which contained a C-terminal His6 tag (apart from JNK1 that contained
an N-terminal His6-tag only). Samples were normally purified by double affinity
chromatography or by ion-exchange close to homogeneity checked by SDS-
PAGE. In vitro ubiquitination and phosphorylation reactions were carried out in
50  mM HEPES pH  7.5,  100  mM NaCl,  5  mM MgCl2,  0.05% IGEPAL,  5%
glycerol,  2 mM DTT. MEKK3 was expressed with the Bac-to-Bac baculoviral
expression  system  with  a  C-terminal  His6-tag  and  an  N-terminal  maltose
binding protein (MBP) tag and purified by double affinity chromatography (using
Ni-NTA and amylose resin, New England Biolabs). GST-MEKK2 was purchased
from Signalchem. MAPKKKs (0.2μM) were first ubiquitinylated in the presence
of ubiquitin (25μM, Boston Biochem) at room temperature for 30' using E1, E2
(0.1 μM, Boston Biochem) and GST-XIAP (0.2 μM, expressed in  E.Coli  and
purified)  similarly  as  described  in  the   Ubiquitination  experiments  section.
Phosphorylation assays were started by adding MAPKKs (5μM) and MAPKs
(5μM) and  additional  0.5  mM fresh  Mg-ATP.  For  non-ubi  reactions samples
were treated exactly the same but XIAP was not added to the reaction mix.
Reactions were stopped with protein loading sample buffer complemented with
20 mM EDTA, boiled and then subjected to SDS-PAGE. Gels were dried before
analysis by phosphorimaging or by Western-blots on a Typhoon Trio+ scanner
(GE  Healthcare).  Western-blots  were  done  by  using  anti-phospho  ERK5
antibody,  anti-phospho  MEK5,  anti-phospho  JNK1  antibody   (9251S,  Cell
Signaling)  and  anti-phospho  MKK7  antibody  (4171S,  Cell  Signaling).  The
constitutive active form of MEK5 (MEK5DD: S311D, T315D) and the kinase
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inactive version of ERK5 (ERK5_KI: D182A) - that was used as substrate in the
in  vitro  kinase  assays  –  were  generated  by  QuickChange  Site-Directed
Mutagenesis or by PCR, and proteins were expressed and purified as described
earlier   JNK1 kinase_dead (KD)  was  expressed with  N-terminal  His6-tag  in
E.Coli Rosetta (DE3) pLsyS (Novagen) and purification was done with nickel
affinity  and  ion  exchange  chromatography  (ResourseQ  1ml  column,  GE
Healthcare).  Dephosphorylated  MKK7  (with  N-terminal  GST-  and  C-terminal
His6-tag)  was  co-expressed  with  λ  phage phosphatase  in  E.Coli  (MG950
vector)  and  purified  by  double  affinity  chromatography  (on  Ni-NTA  and
Glutathione sepharose). For the myeline basic protein (MyBP) phsophorylation
experiments the reaction was started by adding  0.5 mM ATP with  ~5 μCi of
ATP(γ32P).  
Expression of GST tagged proteins and their purification
XIAP-GST  (M1-S497),  XIAP-BIR1-GST  (M1-S123),  XIAP-BIR2-GST  (L121-
S261),  XIAP-BIR3-GST  (S261-E350),  XIAP-BIR1+2-GST  (M1-S261),  XIAP-
BIR1+2+3-GST (M1-E350), XIAP-ΔRING-GST (M1-L449) or  GST alone were
transformed  into  BL21-CodonPlus  competent  cells  and  transformation  and
protein purification was done according to manufacturer’s instructions. Briefly,
the  transformed cells  were  grown in  a liquid  culture  at  37°C overnight  with
Chloramphenicol  and Ampicillin  with  constant  shaking.  Part  of  this  overnight
culture was then added to fresh LB media and incubated at 37C till it reached
OD600 0.6. Transformed bacteria were then induced with 1 mM IPTG for 4 h at
37°C. The cells were pelleted and lysed in GST lysis buffer (50 mM Hepes pH
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7.5, 150 mM NaCl, 1 mM EDTA, 5% Glycerol, 0.1% NP-40), 1 mM DTT and 1
mM protease inhibitor cocktail (Calbiochem). The GST proteins were bound to
glutathione-sepharose beads (GE Healthcare).  MEKK2-GST and MEKK3-GST
were obtained from SignalChem (active MEKK2, Cat. No. M10-10G-20; active
MEKK3,  Cat.  No.  11-10G-20)  and  MEK5-GST  from  Abnova  (Cat.  No.
H00005607-P01).
In vitro translation
In vitro translation was performed using the TNT® T7 Coupled Reticulocyte
Lysate Systems from Promega following the manufacturer’s protocol (Cat.
No.  L4610).  Briefly,  1  μg  of  template  DNA was  mixed  in  the  following
reaction: 25 μl TNT® lysates, 2 μl TNT® Reaction Buffer, 1 μl TNT® T7 RNA
Polymerase, 1 mM Amino Acids Mixture, minus Leucine, 1 mM Amino Acids
Mixture, minus Methionine and 40 units of RNasin® Ribonuclease Inhibitor,
and  incubated  at  30°C  for  90  minutes.  pcDNA3.1B-myc/his-MEKK2-wt,
pcDNA3.1B-myc/his-MEKK2-K47A,  pcDNA3.1B-myc/his-MEKK2-K384M,
pcDNA3.1B-myc/his-XIAP plasmids were used as template.
Pull down experiments
Glutathione Sepharose™ (GE Healthcare, Cat. No. 17-0756-05) were washed
and  equilibrated  in  the  so-called  “GST Pull-down Buffer”  (GPB):  50mM Tris
pH7.5, 150mM NaCl, 1% NP40, 1 mM DTT. For each condition, 50 μl of beads
were resuspended in 300 μl of GPB and incubated on rotator for 2 hours at 4°C
with 1 μg of GST protein. The beads were then washed 3 times with GPB and
incubated on rotator for 1 hour at 4°C with 100 mg/ml BSA-GPB solution. After
washing 3 times, beads were finally incubated on rotator for 2 hours at 4°C with
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purified  XIAP  protein  or  in  vitro translated  protein.  The  final  washing  was
performed with GPB containing either 150 mM or 250 mM NaCl. Buffer was
completely removed using an insulin syringe and samples were then prepared
for SDS-PAGE.
For MBP pull-down experiments, first the amylose resin (New England BioLabs)
was equilibrated with binding buffer (20mM Tris, 100 mM NaCl, 0.1% IGEPAL,
2mM β-mercaptoethanol) and 10 μg immobilized MBP-fusion protein (and MBP
protein as negative control) was incubated in the presence of 10  μM prey in
200 μl binding buffer for 30 min at room temperature. Binding reactions typically
contained 10-20 μl resin saturated with baits. Amylose beads were pelleted with
centrifugation and washed three times. Retained proteins were eluted from the
resin  with  SDS loading  buffer.  Samples  were  subjected  to  SDS-PAGE and
stained with Coomassie staining.
Immunoprecipitation
To immunoprecipitate endogenous proteins, HeLa or MEFs cells were seeded
on 10 cm dishes and if required, transfected after 24 h and then lysed 48 h post
transfection.  Next  day,  80  %  confluent  cells  were  lysed  with  lysis  buffer
containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 % NP-40, 0.5 % Triton X-
100, 1 mM NaVO3, 10 mM Na-pyrophosphate, 1 mM NaF, 0.5 mM EDTA, 0.5
mM EGTA, 1 mM DTT, 1 µg/ml Aprotinin, 0,5 µg/ml Leupeptin, 10 µM Pepstatin
for 30 min on ice. Lysates were cleared by centrifugation for 15 min at 14,000
rpm.  Endogenous  MEKK2,  MEKK3  or  XIAP  was  then  immunoprecipitated
overnight.  The  antigen-antibody  complexes  were  precipitated  by  sepharose
coupled protein A/G beads (Roche,  Cat.  No. 11-134-515-001 & 11-243-233-
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001). The beads were washed with the lysis buffer, and bound proteins were
analyzed by SDS-PAGE and immunoblotting.
For  immunoprecipitation  of  co-expressed  proteins  in  293T  cells,  we  have
transfected  293T cells  with  various  plasmids  using  GeneJuice® transfection
reagent (Novagen®, Merck Millipore, Cat. No. 70967). The cells were lysed at 48
hours  post-transfection  and  proteins  were  immunoprecipitated  as  mentioned
above. Controls IPs were performed with IgG isotype control antibodies (Santa
C ruz).
For immunoprecipitation of the entire  protein complex (MEKK2-ERK5-MEK5)
HeLa cells stably overexpressing ERK5-FLAG and MEK5-V5 were employed.
Two days post-transfection with siXIAP 3’UTR using RNAiMax the cells were
lysed in RIPA buffer (250 mM NaCl, 50 mM Tris pH 7.5, 10% Glycerine, 1%
Triton X-100, 1mM DTT, 1% of Protease Inhibitor Cocktail Set I (Calbiochem))
for 30 minutes at 4°C. Lysates were cleared by centrifugation for 15 min at
14,000  rpm.  FLAG-ERK5  fusion  protein  was  isolated  using  ANTI-FLAG  M2
Magnetic beads (Sigma). For each condition 10 µL magnetic beads were used
and incubated with the lysate for 4 hours at 4°C. The immunoprecipitation and
subsequent  elution  with  FLAG  peptides  was  performed  according  to  the
manufacturer’s instructions (Sigma). 
Mass spectrometry 
Samples from the in-vitro ubiquitination assay were cleaned and fractionated
using SDS-PAGE and digested in-gel using trypsin as described by earlier with
minor modifications. The sample was alkylated with chloroacetamide to reduce
32
formation of lysine modifications with the same atomic composition as the di-
glycine  modification  .  Before  performing  LC-MS  analysis,  peptides  were
desalted  using  C18 StageTips  .  Peptides  were  loaded  with  Solvent  A (0.5%
acetic  acid)  to  an  Easy-nLC II  coupled to  an  Orbitrap  Elite  (Thermo Fisher
Scientific)  and separated using  a  C18 fused silica  emitter  packed in-house.
Elution was performed using a segmented gradient of 5-50-90% of solvent B
(80% ACN in 0.5% acetic acid) with a constant flow of 200  nL/min over 87 min.
Full scan MS spectra were acquired in the Orbitrap mass analyser in the range
of 300 – 2,000 Th at a resolution of 120,000. The 20 most intense ions were
successively isolated for CID fragmentation in the linear ion trap at a target
value  of  5,000 charges.  Ions selected for  fragmentation  were  included in  a
dynamic exclusion list for 60s. 
The acquired data was processed using the MaxQuant software suite  which
contains  the  Andromeda  search  engine  .  Mass  spectra  data  was  searched
against a human database containing 73,929 entries (www.uniprot.org, Protein
Dataset in FASTA format, downloaded on the 18.01.2012) and 248 frequently
seen  laboratory  contaminants.  Carbamidomethylation  (Cys)  was  defined  as
fixed, and protein N-terminal acetylation, oxidation (Met) and GlyGly (Lys) were
defined as variable modifications. Initial mass tolerance was set to 7  ppm for
precursor ions, and to 0.5 Da for fragment ions. False discovery rate was set to
1% at the protein, peptide and modification levels. 
Myoblast Differentiation
Human  Skeletal  Muscle  Myoblast  (HSM)  were  seeded  in  12-wells  plate  at
10,000  cells  per  well.  When  immunofluorescence  was  needed,  cells  were
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seeded out on glass coverslips, previously coated with purified bovine collagen
solution from Nutragen® (Advanced BioMatrix, Cat. No. 5010-D) for at least 2
hours. At 70-80% confluency cells were transfected with siRNAs as explained
above.  The  following  day  differentiation  was  started  by  first  rinsing  residual
growth medium with PBS and then by adding differentiation medium (ZenBio,
see above). Transfection of siRNA was performed every two days to ensure the
proteins knock-down. In order to inhibit ERK5 activation, cells were treated with
5 μM of XMD 8-92 (R&D Systems, Cat. No. 4132) or with the equivalent amount
of DMSO, every two days while renewing the differentiation medium. Cells were
lysed at various time points by adding 5X laemmli and prepared for SDS-PAGE
and immunoblotting. For the immunofluorescence, cells were fixed with 2% PFA
for 20 minutes at room temperature (RT). After washing 3 times with PBS, cells
were permeabilized 7 minutes at RT with 0.1% Triton-X100 diluted in PBS. Cells
were then blocked in 5% BSA-PBS overnight at +4°C. The first antibody against
Myosine Heavy Chain (MHC) was added at a dilution of 1/200 overnight at +4°C
and was followed by an overnight incubation with the secondary anti-mouse-
Cy3 antibody at +4°C. The DAPI staining was obtained by incubating the fixed
cells in 1/5000 Hoechst 33342 solution for 10 minutes at RT. Finally cover slips
were fixed on slides using Mowiol 4-88 reagent (Calbiochem, Cat. No. 475904).
The images were  acquired  using  a  Leica  fluorescent  microscope  (DMIRE2)
fitted with a digital camera with both high NA and low NA 10X objectives. 
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Figure Legends
Figure 1
Depletion of  XIAP leads to enhanced activation of  the MEKK2/3-MEK5-
ERK5 pathway. (A) Depletion of XIAP increases the basal phosphorylation of
ERK5. HeLa cells were transiently transfected with Control or with four different
XIAP siRNAs.  Total  lysates  were  analyzed  by  western  blotting  with  various
antibodies.  (B)  Depletion of  XIAP enhances the strength of ERK5 activation
HeLa-MEF2  cells  were  transiently  transfected  with  siControl  or  siXIAP  or
siERK5 and then stimulated with 10% FCS after serum starvation. Total lysates
were  analyzed  by  western  blotting.  (C)  Depletion  of  XIAP enhances  MEF2
transcriptional activity. HeLa cells stably expressing the MEF2-luciferase (luc)
reporter gene were transiently transfected with siRNAs against XIAP, ERK5 or
both.  Cells  were  then  lysed  and  the  luciferase  activity  was  measured  and
normalized to the Control activity as mentioned in the methods section. (Shown
is  the  quantification  of  five  independent  experiments  with  *=p<0.05  and
**=p<0.01) (D) Loss of XIAP in MEFs also enhances ERK5 phosphorylation.
WT and XIAP-/- MEFs were stimulated with 25 ng/ml of FGF-2. Total  lysates
were analyzed by western blotting. (E, F and G) XIAP-mediated effect on ERK5
phosphorylation is dependent of MEKK2, MEKK3 and MEK5. HeLa cells were
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co-transfected with  siRNAs against  XIAP and/or  MEKK2 (E),  MEKK3 (F)  or
MEK5 (G). Total lysates were analyzed by western blotting as indicated.
Figure 2
Characterizing the mode of interaction between XIAP and MEKK2/3-MEK5
(A)  XIAP binds  to  MEKK2  and  MEKK3  in  vitro.  Purified  XIAP protein  was
incubated with MEKK2-GST or MEKK3-GST and GST pull-down was performed
as described in Experimental procedures. (B) XIAP binds to MEKK2  in vivo.
Endogenous XIAP and MEKK2 were immunoprecipitated from HeLa cell lysates
and  IP  fractions  were  analyzed  by  western  blotting  for  co-precipitation  of
complex components. (C) Mutation in the PB1 domain of MEKK2 prevents XIAP
binding. XIAP-GST protein was incubated with  in  vitro translated MEKK2-wt,
MEKK2-K47A and  GST  pull-down  was  performed.  Total  lysates  and  GST
fraction were analyzed by western blotting. (D) XIAP does not bind to MEK5.
MEK5-GST protein was incubated with either  in vitro translated MEKK2-wt or
XIAP-wt  protein  and  GST pull-down was  performed.  Total  lysates  and GST
fraction  were  analyzed  by  western  blotting.  (E)  XIAP competes  for  MEKK2
binding  to  MEK5.  MEK5-GST protein  was incubated  with  in  vitro translated
MEKK2-wt  in  the  presence  or  absence  of  increasing  amounts  of  in  vitro
translated XIAP-wt and subjected to GST pull-down. The amounts of XIAP in
the supernatant (SN) were tested.  The relative amounts of co-precipitating of
MEKK2  was  quantified  and  the  mean  of  three  independent  experiments  is
shown as  a  graph  with  **=p<0.01  and  ***=p<0.001.  (F).  Depletion  of  XIAP
improves  MEK5  binding  to  MEKK2  in  vivo.  A431  cells  were  transiently
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transfected with siControl or siXIAP, stimulated with 10% FCS and endogenous
MEKK2 was immunoprecipitated. The relative fold increase in the amount of
MEK5 band co-precipitating with MEKK2 was quantified and presented below
the blots. 
Figure 3
XIAP  promotes  K63-linked  Ubiquitin  chain  formation  on  MEKK2  and
MEKK3 in a RING dependent manner. (A) XIAP mediates ubiquitination of
MEKK2 after ERK5 activation in vivo.  WT and XIAP-/- MEFs were stimulated
with  25  ng/ml  of  FGF-2  for  the  indicated  time  points  and  MEKK2  was
immunoprecipitated.  Total  lysates  and IP fraction  were  analyzed by  western
blotting. (B) XIAP promotes MEKK2 ubiquitination in vitro. In vitro ubiquitination
of purified MEKK2 by XIAP was performed and analyzed by western blotting
using MEKK2 antibody. (C) K63-ubiquitination of MEKK2 is dependent of XIAP-
E3 ligase activity. Flag-MEKK2 and HA-Ubiquitin were transfected in HEK293T
cells with myc-EV, XIAP or XIAP-H467A, an XIAP RING mutant. MEKK2 was
immunoprecipitated using Flag antibody and ubiquitination was checked using
western blot analysis with HA (ubiquitin) and K63-linkage specific antibodies. *
denotes overexpressed XIAP.  (D and E) XIAP promotes MEKK2 and MEKK3
K63-specific ubiquitination in vitro. MEKK2 (D) & MEKK3 (E) were subjected to
in  vitro ubiquitination  and  MEKK2  or  MEKK3,  respectively,  were
immunoprecipitated  from the samples.  Western  blot  analysis  was performed
using K63-linkage specific antibody. (F) ERK5 phosphorylation is dependent on
XIAP RING domain. WT and XIAP ΔRING knock-in MEFs were stimulated with
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25 ng/ml of  FGF-2 for indicated time points and phosphorylation of ERK5 was
detected by immunoblots.(G) XIAP-/- MEFs were stably reconstituted with either
pEGZ-Flag EV, pEGZ-Flag-XIAP wt or pEGZ-Flag-XIAP H467A were stimulated
with 25 ng/ml of FGF-2 for the indicated time points. The activation of ERK5
was monitored by immunoblots. 
Figure 4
XIAP mediated MEKK2/3 ubiquitination directly impedes ERK5 activation.
(A)  MEKK2  activity  on  MEK5  is  not  affected  by  ubiquitination.  In  vitro
ubiquitination  of  MEKK2  was  performed  (lower  panel)  and  then  was
immunoprecipitated  out  from  the  ubiquitination  mix.  Beads  with  non-
ubiquitinated  (-NU)  and  ubiquitinated  (-(Ubi)n)  MEKK2  were  employed  for
kinase  assay  with  recombinant  MEK5  as  substrate  (higher  panel).  Western
blotting with phospho-specific MEK5 antibody was used as a readout for the
experiment.  (B)  MEKK3 activity on a general  kinase substrate (myelin basic
protein,  MyBP)  is  not  affected  by  ubiquitination.  In  vitro  ubiquitination  of
MEKK3-MBP was  performed  as  described  in  Experimental  procedures  and
checked  by  Western  Blot  (right  panel).  Non-ubiquitinated  (-NU)  and
ubiquitinated (-(Ubi)n) MEKK3 was incubated with 20 μM MyBP in the presence
of ATP(γ)P32 and MyBP phosphorylation was monitored by phosphorimaging
(left  panel).  (C)  XIAP-mediated  ubiquitination  interferes  with  ERK5
phosphorylation  in  the  reconstituted  MEKK2-MEK5-ERK5  MAPK  module
(higher panel). Similar results were found in MEKK3-MEK5-ERK5 reconstitution
experiments (lower panel). ERK5 phosphorylation by MEK5 was monitored by
western  blots  (mutationally  inactivated  ERK5  was  used  in  all  experiments,
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ERK5_KI D182A). MEKK2 and MEKK3 were ubiquitinated as described for (B)
and then an in vitro kinase assay was started by adding additional 1mM ATP
and recombinantly expressed and purified MEK5 and ERK5 (1 μM and 5 μM,
respectively).  (D)  XIAP-mediated  ubiquitination  interferes  with  ERK5
phosphorylation  in  the  reconstituted  MEKK3-MEK5-ERK5  MAPK  module
without any effect on MEK5 activation. MEK5 and ERK5 phosphorylation were
monitored  by  western  blots  (mutationally  inactivated  ERK5  was  used  in  all
kinase assays, ERK5_KI D182A). MEKK3 was ubiquitinated and then an in vitro
kinase assay was performed as described for (C). (E) Ubiquitination does not
interfere with MEK5 mediated phosphorylation of ERK5, as the constitutively
activated  form  of  MEK5  (MEK5DD)  activates  ERK5  independent  of  the
presence of XIAP. 
Figure 5
Functional  significance  of  MEKK2/3  ubiquitination  (A)  Ubiquitination  of
MEKK2  promotes  its  homodimerization.  Purified  GST-tagged  MEKK2  was
subjected to  in vitro ubiquitination.  In vitro transcribed and translated MEKK2
was added to the non-ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK2. In
vitro  ubiquitination  mix  and  GST  pulldown  was  performed  as  stated  in
experimental procedures section. Homodimerization of MEKK2 was analyzed
by  western  blotting.  (B)  Ubiquitination  of  MEKK2  promotes  its
heterodimerization with MEKK3. Purified MEKK2 protein was subjected to  in
vitro ubiquitination. Purified MEKK3 was added to the non-ubiquitinated (-NU)
and  ubiquitinated  (-(Ubi)n)  MEKK2  samples  and  MEKK2  was  MEKK2  was
pulled  downimmunoprecipitated.  Co-precipitated  MEKK3 was  detected  using
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western blotting.   (C) Ubiquitination of MEKK2 does not impair MEK5 binding.
In vitro ubiquitination of MEKK2 by XIAP was performed as stated above. His-
tagged  ubiquitin  was  pulled  down  from  non-ubiquitinated  (-NU)  and
ubiquitinated  (-(Ubi)n)  MEKK2  samples  using  Ni-NTA beads  as  detailed  in
Materials  and  Methods  section.  Co-precipitated  MEK5  was  analyzed  using
western blotting. (D) Ubiquitination of MEKK3 does not impair MEK5 binding.
Ubiquitination of MBP-MEKK3 was carried out after the protein was bound to
amylose  resin  and  non-ubiquitinated  (-NU)  and  ubiquitinated  (-(Ubi)n)  MBP-
MEKK3 was used for  pulling  down GST-MEK5.  Samples  were  subjected to
SDS-PAGE and stained with Coomassie. (E) MEKK2/3 and MEK5 binding is
mediated  through  their  PB1  domains  in  the  MEKK2/3-MEK5-ERK5  ternary
complex.  The  structural  model  of  the  ternary  complex  is  shown  in  surface
representation . (F) Ubiquitination of MEKK2 impairs ERK5 binding to MEK5.
The trimeric  complex  formation  between MEKK2-MEK5-ERK5 was analyzed
using non-ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK2. MBP-tagged
MEK5 was used for pulling down GST-MEKK2 and GST-ERK5. Background
binding of MEKK2 and ERK5 to Amylose resin was tested as a control.  (G)
Schematic  representation  of  the  MEKK2/3-MEK5-ERK5  module.  Ubiquitin
conjugated to MEKK2/3 competes with the non-canonical interaction between
the  MEK5  PB1  domain  and  ERK5.  The  XIAP-cIAP1  complex  promotes
MEKK2/3 K63- ubiquitination, which, in turn, interferes with the recruitment of
ERK5  to  the  MEKK2/3-MEK5  binary  complex.  (Kinases  are  depicted
schematically  with  their  classical  N-  and  C-terminal  bipartite  lobe  structure
where “P” indicates activation loop phosphorylation sites, “*” marks the position
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of the kinase active site  and the rectangle at  the back of  the ERK5 kinase
domain shows the MEK5 docking motif binding to the MAPK docking groove .
Figure 6
Depletion  of  XIAP enhances  myoblasts  differentiation. (A)  Depletion  of
XIAP  leads  to  an  increase  in  ERK5  phosphorylation  in  undifferentiated
myoblasts. Undifferentiated HSM were transiently transfected with siControl or
siXIAP.  (B)  Depletion  of  XIAP  leads  to  an  increase  in  ERK5  activation  in
undifferentiated  myoblasts.  Undifferentiated  HSM cells  stably  expressing  the
MEF2-luciferase (Luc) reporter gene were transiently transfected with siControl
or siXIAP. Part of the lysates was used for western blot detection and another
part  to measure the luciferase activity.  (Shown is the fold increase of MEF2
activity  upon  XIAP knock-down)  (C  and D)  Depletion  of  XIAP  leads  to  an
increase  of  myoblasts  differentiation.  HSM were  transiently  transfected  with
siControl  or siXIAP and differentiation was started the next day. Transfection
was performed every two days and media was changed every following day.
Coverslips were fixed and stained everyday as described in methods. (Shown in
(C) are data from a representative experiment from Day 0, Day 4 and Day 7).
Polynucleation  of  MHC  positive  cells  was  quantified  from  four  independent
experiments and the average fold increase is shown in (D). (E and F) Depletion
of  XIAP  leads  to  an  increase  in  ERK5  phosphorylation  and  expression  of
differentiation markers in myoblasts. HSM were transfected and differentiated
as  described  for  (C).  Cells  were  lysed,  run  on  SDS-PAGE  and  blotted  for
various  differentiation  markers  (E).  Increase  in  ERK5  phosphorylation  was
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quantified from three independent experiments and the average fold increase is
shown in (F) (*=p<0.05, **=p<0.01).
Figure 7
Depletion of MEKK2, MEKK3 or ERK5 inhibits the enhanced differentiation
triggered by XIAP depletion. (A) HSM cells were transiently co-transfected
with siRNAs against XIAP and MEKK2 or ERK5 and differentiation was initiated
with  the  appropriate media  the  next  day.  Coverslips  were fixed and stained
everyday as described (Shown in (A) is data from Day 6 of differentiation). (B)
HSMs were transiently co-transfected with siRNAs against XIAP and MEKK3
and differentiated as described for (A). (C) Polynucleation of MHC positive cells
at Day 6 was quantified and the average fold increase is shown in (C) (left
panel,  N=1;  middle  panel,  N=1;  right  panel,  N=3  with  *=p<0.05  and
***=p<0.001). (D) HSMs were transfected and differentiated as described for
panel  A.  Cells  were  lysed,  run  on  SDS-PAGE  and  blotted  for  various
differentiation markers. (E) Schematic model of MEKK2 ubiquitination by XIAP
and its effect  on the MEKK2/3-MEK5-ERK5 pathway in response to  various
stimuli. XIAP regulates this cascade by direct interaction and ubiquitination. At
steady state, XIAP competes with MEK5 in binding to MEKK2. Upon stimulation
with growth factors, XIAP-cIAP-1 complex ubiquitinates MEKK2/3 thus leading
to  the  inactivation  of  ERK5.  Loss  of  XIAP  promotes  human  myogenic
differentiation  in  a  MEKK2/3-ERK5  dependent  manner.  Depending  on  the
stimuli, MEKK2/3 might bind and activate other effectors like MKK7 or p62 thus
leading to JNK or NFκB activation respectively. 
4
Supplementary Figure legends
Figure S1
(A) HeLa cells were transiently transfected with siRNA against XIAP or cIAP1
and the activation of ERK5 was assessed by immunoblots.  (B) HTEpC cells
were transiently transfected with siControl or siXIAP and the phosphorylation of
ERK5 and the depletion of XIAP were monitored. (C) BT474 cells were transi-
ently transfected with siRNA against XIAP  and phosphorylation of ERK5 and
various proteins was detected by immunoblots. (D) HeLa cells were transfected
with either XIAP-3’UTR siRNAs alone or together with Flag–XIAP construct. The
activation of ERK5 was monitored by immunoblots. (E)  HeLa cells were co-
transfected with siRNAs against XIAP and C-RAF and the activation of ERK5
was analyzed.  (F) HeLa cells stably transduced with shRNA against Rac1 were
transiently transfected with siRNA against XIAP (left panel) or (G) cIAP1 (right
panel) and the phosphorylation of ERK5 was monitored by immunoblots. 
Figure S2
(A)  Details  of  XIAP GST tagged  constructs.  (B and  C)  Full  length  XIAP is
needed for binding to MEKK2. In vitro translated MEKK2-wt protein was incub-
ated with different GST constructs of XIAP and GST pull-down was performed.
The reticulolysates and GST fraction were analyzed by western blotting. Details
of the XIAP constructs are shown in S2A. In (C) longer exposure of MEKK2 blot
was shown (*). (D) Depletion of XIAP leads to an increase in MEK5 binding to
MEKK2  in vivo. HeLa cells were transfected with siControl or siXIAP and en-
4
dogenous  MEKK2  was  immunoprecipitated  with  the  specific  antibody.  Total
lysates and IP fraction were analyzed by western blotting. 
Figure S3
(A) cIAP1 promotes ubiquitination of MEKK2  in vitro.  In vitro ubiquitination of
purified MEKK2 by cIAP1 was performed as stated in Materials and Methods
section and analyzed by western blotting using MEKK2 antibody. (B) XIAP and
cIAP1 promote ubiquitination of MEKK3 in vitro. Purified MEKK3 was subjected
to in vitro ubiquitination by XIAP and cIAP1 and results were analyzed by west-
ern blotting using MEKK3 antibody. (C) K63-ubiquitination of MEKK2 is depend-
ent of cIAP-E3 ligase activity. Flag-MEKK2 and HA-Ubiquitin were transfected in
HEK293T cells with myc-EV, cIAP1 or cIAP1-H588A mutant. MEKK2 was im-
munoprecipitated  using  Flag  antibody  and  ubiquitination  was checked using
western  blot  analysis  with  HA  and  K63-linkage  specific  antibodies.  (D)
HEK293T cells were transfected with XIAP, MEKK2 or both, together with the
Luciferase and the Renilla reporter genes. The luciferase activity was meas-
ured, normalized to Renilla activity and the fold increase of four independent ex-
periments is shown (*=p<0.05). (E and F) XIAP promotes K63 specific-ubiquiti-
nation of MEKK2 and MEKK3 in vitro.  In vitro ubiquitination of purified MEKK2
(E) and MEKK3 (F) by XIAP in the presence of various ubiquitin mutants was
performed as stated in Materials and Methods section and analyzed by western
blotting using MEKK2 (E) or MEKK3 (F) antibody.
Figure S4
4
Characterization of the potential ubiquitination sites on MEKK2 targeted
by XIAP. (A) Enlisted are the lysines found to be ubiquitinated in MEKK2 and
MEKK3 by XIAP and cIAP1. MEKK2 and MEKK3 were ubiquitinated in vitro us-
ing either cIAP1 or XIAP and run on an SDS-PAGE gel. The gel was stained
with Coomassie and the observed MEKK2/3 ubiquitination bands were spliced
and subjected to in-gel trypsin digestion. The peptides were then analyzed for
ubiquitinated lysine residues by mass spectroscopy. (B) Representation of the
ubiquitination sites on MEKK2 and MEKK3 by XIAP and cIAP1. (C) Mutation of
K450 on MEKK2 enhances the activation of ERK5. HeLa cells were transiently
transfected with either MEKK2 wt-V5, MEKK2 K360R-V5 or MEKK2 K450R-V5
constructs. Total lysates were analyzed by western blotting. (D) Stable expres-
sion of MEKK2 K450R mutant enhances basal level of phosphorylated ERK5.
HeLa  cells  stably  expressing  either  MEKK2 wt-Flag  or  MEKK2 K450R-Flag
were transiently transfected with either XIAP-3’UTR or MEKK2-3’UTR siRNAs.
Total lysates were analyzed by western blotting.
Figure S5 
XIAP-mediated  ubiquitination  doesn't  interfere  with  JNK  and  MKK7  phos-
phorylations  in  the  reconstituted  MEKK3/MKK7/JNK  and  MEKK2/MKK7/JNK
modules.
Figure S6
The trimeric  complex  formation  between MEKK2-MEK5-ERK5 was analyzed
using non-ubiquitinated and ubiquitinated MEKK2. GST-tagged MEK5 was used
for immunoprecipitating GST-MEKK2 and GST-ERK5 using rabbit monoclonal
5
antibody against MEK5. Difference between binding of ERK5 to MEK5 in the
presence of ubiquitinated and non-ubiquitinated MEKK2 was analyzed by west-
ern blotting.
Figure S7
Pharmacological  inhibition  of  ERK5  prevents  the  enhanced  differentiation
provoked by XIAP depletion. HSM were transiently transfected with siXIAP and
treated with DMSO or 5 μM of XMD 8-92 and differentiation was started the day
after.  Transfection  was  performed  every  two  days  and  media  and  drug
treatment was renewed every following day. Coverslips were fixed and stained
everyday as described in Material & Methods (Shown in (A) are only Day 0, Day
4 and Day 7). (B) Polynucleation of MHC positive cells at Day 6 was quantified
and the average fold increase is shown in the upper right panel. (C)In parallel,
cells  were  lysed,  run  on  SDS-PAGE  and  blotted  for  various  differentiation
markers (lower panel).
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Figure 1
Depletion of XIAP leads to enhanced activation of the MEKK2/3-MEK5-ERK5 pathway. 
(A) Depletion of XIAP increases the basal phosphorylation of ERK5. HeLa cells were 
transiently transfected with Control or XIAP siRNAs. Total lysates were analyzed by 
western blotting with various antibodies. (B) Depletion of XIAP enhances the strength of 
ERK5 activation HeLa-MEF2 cells were transiently transfected with siControl or siXIAP or 
siERK5 and then stimulated with 10% FCS after serum starvation. Total lysates were 
analyzed by western blotting. (C) Depletion of XIAP enhances MEF2 transcriptional activity. 
HeLa cells stably expressing the MEF2-luciferase (luc) reporter gene were transiently 
transfected with siRNAs against XIAP, ERK5 or both. Cells were then lysed and the 
luciferase activity was measured and normalized to the Control activity as mentioned in the 
methods section. (Shown is the quantification of five independent experiments with 
*=p<0.05 and **=p<0.01) (D) Loss of XIAP in MEFs also enhances ERK5 phosphorylation. 
WT and XIAP-/- MEFs were stimulated with 25 ng/ml of FGF-2. Total lysates were analyzed 
by western blotting. (E, F and G) XIAP-mediated effect on ERK5 phosphorylation is 
dependent of MEKK2, MEKK3 and MEK5. HeLa cells were co-transfected with siRNAs 
against XIAP and/or MEKK2 (E), MEKK3 (F) or MEK5 (G). Total lysates were analyzed by 
western blotting as indicated.
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A B C
E
F
D
150
100
75
100
50
25
XIAP
MEKK3
MEKK2
In
pu
t
GST Pull-Down
Purified XIAP+ + +
MEKK2-GST- + -
MEKK3-GST- +-
GST
kDa
MEKK2
XIAP
Ig
G
 m
ou
se
Ig
G
 r
ab
bi
t
IP
 X
IA
P
IP
 M
E
K
K
2
Total Lysates
Ig
G
 m
ou
se
Ig
G
 r
ab
bi
t
IP
 X
IA
P
IP
 M
E
K
K
2
IP fraction
kDa
50
75
HeLa
75
75
25
Input
MEKK2
XIAP-GST- +
GST pull down
w
t
K
47
A
- +
wt K4
7A
MEKK2
GST (XIAP)
GST
MEKK2
kDa
75
75
50
75
50
75
50
37
MEKK2
XIAP
- + - +
- - + +
+ + - - MEKK2 (TNT)
MEK5-GST
XIAP (TNT)
MEK5
GST
In
pu
t (
10
%
)
GST pull down
kDa
75
75
kDa
1.0 0.6 0.3MEKK2 relative 
expression
MEK5-GST
XIAP wt
MEKK2 wt+ + + +
+ -
- + + +
MEK5
MEKK2
In
pu
t
0,0
0,5
1,0
1,5 ***
*** **
No
XIAP
XIAP
(1:1)
XIAP
(1:2)
MEKK2
MEK5
MEK5
pERK5
MEKK2
IP
 M
E
K
K
2
To
ta
l L
ys
at
es
XIAP
0 5 15 0 5
siControl
15
siXIAP
Actin
100
50
50
50
37
75
75
kDa
A431
FCS
MEK5/MEKK2: 1.0 0.9 1.0 1.5 1.7 2.0
Characterizing the mode of interaction between XIAP and MEKK2/3-MEK5 (A) XIAP 
binds to MEKK2 and MEKK3 in vitro. Purified XIAP protein was incubated with MEKK2-
GST or MEKK3-GST and GST pull-down was performed as described in Experimental 
procedures. (B) XIAP binds to MEKK2 in vivo. Endogenous XIAP and MEKK2 were 
immunoprecipitated from HeLa cell lysates and IP fractions were analyzed by western 
blotting for co-precipitation of complex components. (C) Mutation in the PB1 domain of 
MEKK2 prevents XIAP binding. XIAP-GST protein was incubated with in vitro translated 
MEKK2-wt, MEKK2-K47A and GST pull-down was performed. Total lysates and GST 
fraction were analyzed by western blotting. (D) XIAP does not bind to MEK5. MEK5-GST 
protein was incubated with either in vitro translated MEKK2-wt or XIAP-wt protein and GST 
pull-down was performed. Total lysates and GST fraction were analyzed by western 
blotting. (E) XIAP competes for MEKK2 binding to MEK5. MEK5-GST protein was 
incubated with in vitro translated MEKK2-wt in the presence or absence of increasing 
amounts of in vitro translated XIAP-wt and subjected to GST pull-down. The relative 
expression of MEKK2 was quantified and the mean of three independent experiments is 
shown as a graph with **=p<0.01 and ***=p<0.001. (F). Depletion of XIAP improves MEK5 
binding to MEKK2 in vivo. A431 cells were transiently transfected with siControl or siXIAP, 
stimulated with 10% FCS and endogenous MEKK2 was immunoprecipitated. The relative 
fold increase in the amount of MEK5 band co-precipitating with MEKK2 was quantified and 
presented below the blots. 
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Figure 3
XIAP promotes K63-linked Ubiquitin chain formation on MEKK2 and MEKK3 in a RING 
dependent manner. (A) XIAP mediates ubiquitination of MEKK2 after ERK5 activation in 
vivo. WT and XIAP-/- MEFs were stimulated with 25 ng/ml of FGF-2 for the indicated time 
points and MEKK2 was immunoprecipitated. Total lysates and IP fraction were analyzed by 
western blotting. (B) XIAP promotes MEKK2 ubiquitination in vitro. In vitro ubiquitination of 
purified MEKK2 by XIAP was performed and analyzed by western blotting using MEKK2 
antibody. (C) K63-ubiquitination of MEKK2 is dependent of XIAP-E3 ligase activity. Flag-
MEKK2 and HA-Ubiquitin were transfected in HEK293T cells with myc-EV, XIAP or XIAP-
H467, an XIAP RING mutant. MEKK2 was immunoprecipitated using Flag antibody and 
ubiquitination was checked using western blot analysis with HA (ubiquitin) and K63-linkage 
specific antibodies. * denotes overexpressed XIAP.  (D and E) XIAP promotes MEKK2 and 
MEKK3 K63-specific ubiquitination in vitro. MEKK2 (D) & MEKK3 (E) were subjected to in 
vitro ubiquitination and MEKK2 or MEKK3, respectively, were immunoprecipitated from the 
samples. Western blot analysis was performed using K63-linkage specific antibody. (F) 
ERK5 phosphorylation is dependent on XIAP RING domain. WT and XIAP ΔRING knock-in 
MEFs were stimulated with 25 ng/ml of FGF-2 for indicated time points and phosphorylation 
of ERK5 was detected by immunoblots.(G) XIAP-/- MEFs were stably reconstituted with 
either pEGZ-Flag EV, pEGZ-Flag-XIAP wt or pEGZ-Flag-XIAP H467A were stimulated with 
25 ng/ml of FGF-2 for the indicated time points. The activation of ERK5 was monitored by 
immunoblots. 
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Figure 4
XIAP mediated MEKK2/3 ubiquitination directly impedes ERK5 activation. (A) 
MEKK2 activity on MEK5 is not affected by ubiquitination. In vitro ubiquitination of MEKK2 
was performed (lower panel) and then was immunoprecipitated out from the 
ubiquitination mix. Beads with non-ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK2 
were employed for kinase assay with recombinant MEK5 as substrate (higher panel). 
Western blotting with phospho-specific MEK5 antibody was used as a readout for the 
experiment. (B) MEKK3 activity on a general kinase substrate (myelin basic protein, 
MyBP) is not affected by ubiquitination. In vitro ubiquitination of MEKK3-MBP was 
performed as described in Experimental procedures and checked by Western Blot (right 
panel). Non-ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK3 was incubated with 20 
μM MyBP in the presence of ATP(γ)P32 and MyBP phosphorylation was monitored by 
phosphorimaging (left panel). (C) XIAP-mediated ubiquitination interferes with ERK5 
phosphorylation in the reconstituted MEKK2-MEK5-ERK5 MAPK module (higher panel). 
Similar results were found in MEKK3-MEK5-ERK5 reconstitution experiments (lower 
panel). ERK5 phosphorylation by MEK5 was monitored by western blots (mutationally 
inactivated ERK5 was used in all experiments, ERK5_KI D182A). MEKK2 and MEKK3 
were ubiquitinated as described for (B) and then an in vitro kinase assay was started by 
adding additional 1mM ATP and recombinantly expressed and purified MEK5 and ERK5 
(1 μM and 5 μM, respectively). (D) XIAP-mediated ubiquitination interferes with ERK5 
phosphorylation in the reconstituted MEKK3-MEK5-ERK5 MAPK module without any 
effect on MEK5 activation. MEK5 and ERK5 phosphorylation were monitored by western 
blots (mutationally inactivated ERK5 was used in all kinase assays, ERK5_KI D182A). 
MEKK3 was ubiquitinated and then an in vitro kinase assay was performed as described 
for (C). (E) Ubiquitination does not interfere with MEK5 mediated phosphorylation of 
ERK5, as the constitutively activated form of MEK5 (MEK5DD) activates ERK5 
independent of the presence of XIAP. 
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Figure 5
Functional significance of MEKK2/3 ubiquitination (A) Ubiquitination of MEKK2 promotes 
its homodimerization. Purified GST-tagged MEKK2 was subjected to in vitro ubiquitination. In 
vitro transcribed and translated MEKK2 was added to the non-ubiquitinated (-NU) and 
ubiquitinated (-(Ubi)n) MEKK2. In vitro ubiquitination mix and GST pulldown was performed 
as stated in experimental procedures section. Homodimerization of MEKK2 was analyzed by 
western blotting. (B) Ubiquitination of MEKK2 promotes its heterodimerization with MEKK3. 
Purified MEKK2 protein was subjected to in vitro ubiquitination. Purified MEKK3 was added 
to the non-ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK2 samples and MEKK2 was 
immunoprecipitated. Co-precipitated MEKK3 was detected using western blotting.  (C) 
Ubiquitination of MEKK2 does not impair MEK5 binding. In vitro ubiquitination of MEKK2 by 
XIAP was performed as stated above. His-tagged ubiquitin was pulled down from non-
ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MEKK2 samples using Ni-NTA beads as 
detailed in Materials and Methods section. Co-precipitated MEK5 was analyzed using 
western blotting. (D) Ubiquitination of MEKK3 does not impair MEK5 binding.  Ubiquitination 
of MBP-MEKK3 was carried out after the protein was bound to amylose resin and non-
ubiquitinated (-NU) and ubiquitinated (-(Ubi)n) MBP-MEKK3 was used for pulling down GST-
MEK5. Samples were subjected to SDS-PAGE and stained with Coomassie. (E) MEKK2/3 
and MEK5 binding is mediated through their PB1 domains in the MEKK2/3-MEK5-ERK5 
ternary complex. The structural model of the ternary complex is shown in surface 
representation [23]. (F) Ubiquitination of MEKK2 impairs ERK5 binding to MEK5. The trimeric 
complex formation between MEKK2-MEK5-ERK5 was analyzed using non-ubiquitinated (-
NU) and ubiquitinated (-(Ubi)n) MEKK2. MBP-tagged MEK5 was used for pulling down GST-
MEKK2 and GST-ERK5. Background binding of MEKK2 and ERK5 to Amylose resin was 
tested as a control. (G) Schematic representation of the MEKK2/3-MEK5-ERK5 module. 
Ubiquitin conjugated to MEKK2/3 competes with the non-canonical interaction between the 
MEK5 PB1 domain and ERK5. The XIAP-cIAP1 complex promotes MEKK2/3 K63- 
ubiquitination, which, in turn, interferes with the recruitment of ERK5 to the MEKK2/3-MEK5 
binary complex. (Kinases are depicted schematically with their classical N- and C-terminal 
bipartite lobe structure where “P” indicates activation loop phosphorylation sites, “*” marks 
the position of the kinase active site and the rectangle at the back of the ERK5 kinase 
domain shows the MEK5 docking motif binding to the MAPK docking groove [23].
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Figure 6
Depletion of XIAP enhances myoblasts differentiation. (A) Depletion of XIAP leads 
to an increase in ERK5 phosphorylation in undifferentiated myoblasts. Undifferentiated 
HSM were transiently transfected with siControl or siXIAP. (B) Depletion of XIAP leads 
to an increase in ERK5 activation in undifferentiated myoblasts. Undifferentiated HSM 
cells stably expressing the MEF2-luciferase (Luc) reporter gene were transiently 
transfected with siControl or siXIAP. Part of the lysates was used for western blot 
detection and another part to measure the luciferase activity. (Shown is the fold increase 
of MEF2 activity upon XIAP knock-down) (C and D) Depletion of XIAP leads to an 
increase of myoblasts differentiation. HSM were transiently transfected with siControl or 
siXIAP and differentiation was started the next day. Transfection was performed every 
two days and media was changed every following day. Coverslips were fixed and 
stained everyday as described in methods. (Shown in (C) are data from a representative 
experiment from Day 0, Day 4 and Day 7). Polynucleation of MHC positive cells was 
quantified from four independent experiments and the average fold increase is shown in 
(D). (E and F) Depletion of XIAP leads to an increase in ERK5 phosphorylation and 
expression of differentiation markers in myoblasts. HSM were transfected and 
differentiated as described for (C). Cells were lysed, run on SDS-PAGE and blotted for 
various differentiation markers (E). Increase in ERK5 phosphorylation was quantified 
from three independent experiments and the average fold increase is shown in (F) 
(*=p<0.05, **=p<0.01).
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Depletion of MEKK2, MEKK3 or ERK5 inhibits the enhanced differentiation 
triggered by XIAP depletion. (A) HSM cells were transiently co-transfected with siRNAs 
against XIAP and MEKK2 or ERK5 and differentiation was initiated with the appropriate 
media the next day. Coverslips were fixed and stained everyday as described (Shown in 
(A) is data from Day 6 of differentiation). (B) HSMs were transiently co-transfected with 
siRNAs against XIAP and MEKK3 and differentiated as described for (A). (C) 
Polynucleation of MHC positive cells at Day 6 was quantified and the average fold 
increase is shown in (C) (left panel, N=1; middle panel, N=1; right panel, N=3 with 
*=p<0.05 and ***=p<0.001). (D) HSMs were transfected and differentiated as described 
for panel A. Cells were lysed, run on SDS-PAGE and blotted for various differentiation 
markers. (E) Schematic model of MEKK2 ubiquitination by XIAP and its effect on the 
MEKK2/3-MEK5-ERK5 pathway in response to various stimuli. XIAP regulates this 
cascade by direct interaction and ubiquitination. At steady state, XIAP competes with 
MEK5 in binding to MEKK2. Upon stimulation with growth factors, XIAP-cIAP-1 complex 
ubiquitinates MEKK2/3 thus leading to the inactivation of ERK5. Loss of XIAP promotes 
human myogenic differentiation in a MEKK2/3-ERK5 dependent manner. Depending on 
the stimuli, MEKK2/3 might bind and activate other effectors like MKK7 or p62 thus 
leading to JNK or NFκB activation respectively. 
